8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Coordinating Action Systems Medicine – Implementation of Systems Medicine across Europe (CASYM)
Date du début: 1 nov. 2012, Date de fin: 30 avr. 2017,
The aim of CASyM is a combined large scale effort to sustainably implement Systems Medicine across Europe. For that purpose CASyM will function as a managing and coordinating platform in bringing together a critical mass of relevant European stakeholders such as Systems Biology scientists, clinicians, programme managers, industry/SMEs as well as healthcare providers and patient organizations. The ...
Voir le projet
24
Participants partenaires
TERMINÉ
Quantitative T cell Immunology (QuanTI)
Date du début: 1 mai 2013, Date de fin: 30 avr. 2017,
The primary objective of this ITN is to train a new generation of European quantitative immunologists, who will be able to address challenges arising in Systems Immunology. This will be achieved with the proposed Network, Quantitative T cell Immunology (QuanTI), that will train 11 ESRs and 4 ERs, bringing together renowned experimental and theoretical scientists from private and academic instituti ...
Voir le projet
12
Participants partenaires
TERMINÉ
Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities (ETOX)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2016,
The eTOX consortium proposes to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This will be achieved by coordinating the efforts of specialists from academia and SMEs in the wide scope of disciplines that are required to move towards a more reliable modell ...
Voir le projet
30
Participants partenaires
TERMINÉ
ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours (ASSET)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,
Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumours (ETs) comprising neuroblastoma, medulloblastoma and Ewing sarcoma, occur early in life, and thus may reveal pathogenetically relevant lesions clearer than adulthood tumours which carry passenger mutations accumulated during life. ASSET will exploit this fact ...
Voir le projet
20
Participants partenaires
TERMINÉ
Contamination and defect control for increased yield for large scale R2R production of OPV and OLED (CLEAN4YIELD)
Date du début: 1 mai 2012, Date de fin: 30 avr. 2015,
While nanotechnology was originally limited to small areas of a few cm2, the quest for lower costs has been the latest years the drive for developing processes utilising larger substrate sizes at increasing throughputs. A typical example is the flat panel display industry where the push to larger gen size and faster processing has resulted in a significant cost reduction. The next challenge here i ...
Voir le projet
18
Participants partenaires
TERMINÉ
Safe Nano Worker Exposure Scenarios (SANOWORK)
Date du début: 1 mars 2012, Date de fin: 28 févr. 2015,
The main goal of Sanowork project is to identify a safe occupational exposure scenario by exposureassessment in real conditions and at all stages of nanomaterials (NM) production, use and disposal.In order to address this and more specifically the issues introduced by NMP.2011.1.3-2 call, we intend to:1. contain hazard and worker exposure potential by developing exposure mitigation strategy based ...
Voir le projet
13
Participants partenaires
TERMINÉ
Histopathologic and Mechanistic Assessment of Angiogenesis Inhibitor Related Toxicities: A Cross-Sectoral, Multi-disciplinary Approach (ANGIOTOX)
Date du début: 1 juil. 2010, Date de fin: 30 juin 2014,
Inhibition of angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a well established therapeutic strategy against cancer. Inhibitors of angiogenesis have been developed to block tumour growth and metastasis, and a number of these inhibitors are now clinically approved. However, contrary to initial expectations, angiogenesis inhibitors can cause a range of toxicities ...
Voir le projet
11
Participants partenaires
TERMINÉ
Flexible, Fast and Future Production Processes (F³ FACTORY)
Date du début: 1 juin 2009, Date de fin: 31 juil. 2013,
The F3 consortium’s vision is that the EU’s chemical industry’s competitive position would be strongly enhanced if it could operate modular continuous plant (F3 plant) which combines world scale continuous plant efficiency, consistency and scalability with the versatility of batch operation. Our project will deliver such a radically new production mode based on: a) Plug–and–play modular chemical ...
Voir le projet